Publisher Correction: Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance

Affiliations

• ¹ Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
• ² Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.
• ³ Department of Pathology, Harvard Medical School, Boston, MA, USA.
• ⁴ Program for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁵ Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁶ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁷ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁸ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. gordon_freeman@dfci.harvard.edu.
• ⁹ Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. dennis_kasper@hms.harvard.edu.
• ¹⁰ Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. arlene_sharpe@hms.harvard.edu.
• ¹¹ Department of Pathology, Harvard Medical School, Boston, MA, USA. arlene_sharpe@hms.harvard.edu.